Drug approvals and failures: implications for alliances

被引：29

作者：

Czerepak, Elizabeth A. ^{[1
,2
]}

Ryser, Stefan ^{[1
,2
]}

机构：

[1] Bear Stearns Hlth Innoventures LLC, New York, NY 10017 USA

[2] Bear Stearns Asset Management, New York, NY 10017 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 03期

关键词：

D O I：

10.1038/nrd2531

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：197 / 198

页数：2

共 10 条

[1]

Drews J., 1996, DRUG INF J, V30, P97

[2]

EDELSON S, 2007, BIOCENTURY, V15, P8

[3] Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes [J].

Keymeulen, B ;

Vandemeulebroucke, E ;

Ziegler, AG ;

Mathieu, C ;

Kaufman, L ;

Hale, G ;

Gorus, F ;

Goldman, M ;

Walter, M ;

Candon, S ;

Schandene, L ;

Crenier, L ;

De Block, C ;

Seigneurin, JM ;

De Pauw, P ;

Pierard, D ;

Weets, I ;

Rebello, P ;

Bird, P ;

Berrie, E ;

Frewin, M ;

Waldmann, H ;

Bach, JF ;

Pipeleers, D ;

Chatenoud, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2598-2608

[4]

LAWRENCE S, 2007, BIOCENTURY, V15, P9

[5]

LAWRENCE S, 2007, BIOCENTURY, V15, P10

[6]

LAWRENCE S, 2008, BIOCENTURY, V16, P20

[7]

SABO S, 2003, CURRENT STATUS TARGE

[8]

2006, BIOCENTURY, V14, P9

[9]

2007, BIOCENTURY, V15, P9

[10]

2006, BIOCENTURY, V14, P10

← 1 →